Department of Urology, Georgetown University Hospital, Washington, DC 20007, USA.
BJU Int. 2013 Aug;112(4):E273-80. doi: 10.1111/j.1464-410X.2012.11776.x. Epub 2013 Mar 4.
What's known on the subject? and what does the study add?: Retrospective data have suggested an increased survival benefit for patients undergoing partial nephrectomy compared to radical nephrectomy, possibly as a result of the avoidance of long-term renalin sufficiency and subsequent sequelae. However, recent level-one evidence has questioned this benefit. Both retrospective studies and randomized controlled trials are not without limitations. There are few population-based data available with respect to the outcomes of partial nephrectomy vs radical nephrectomy. Additionally, there are no population-based studies analyzing the surgical approach (minimally-invasive vs open), as well as other modalities, such as ablation and surveillance. Finally, there is very little information available on the potential differences in cost for each approach. The present study comprises the first comprehensive population-based analysis of the trends, outcomes and costs of all treatment modalities for T1a renal masses from 2005 to 2007.
To perform a comprehensive analysis of the outcomes and costs for treatments for small renal masses (SRM) using a population-based approach. Partial nephrectomy may be associated with improved survival, although level-one evidence has questioned this survival advantage.
Using Surveillance, Epidemiology and End Results-Medicare data, we identified 1682 subjects who were diagnosed with SRM from 2005 to 2007. Treatment included open radical nephrectomy (ORN; n = 404), minimally-invasive radical nephrectomy (MIRN; n = 535), open partial nephrectomy (OPN; n = 330), minimally-invasive partial nephrectomy (MIPN; n = 160), ablation (n = 211) and surveillance (n = 42). Postoperative complications, renal insufficiency diagnosis, overall mortality, cancer-specific mortality and postoperative costs were compared. Covariates were balanced before outcomes analysis using propensity score methods.
Although the use of nephron-sparing surgery (NSS) increased over the study period, radical nephrectomy remained the predominant approach for SRM in 2007. Minimally-invasive approaches had shorter lengths of stay (P < 0.001), whereas open approaches had more overall complications, respiratory complications and intensive care unit admissions (all P < 0.003). MIRN and ORN were associated with more peri-operative medical complications, acute renal failure, haemodialysis use and long-term chronic renal insufficiency diagnosis vs NSS (all P < 0.001). Ablation, MIRN and ORN were associated with the highest overall mortality rates (P < 0.001), whereas MIRN and ORN were associated with the highest cancer-specific mortality rates (P < 0.001). Treatment costs were lowest for surveillance ($2911) followed by ablation ($10730), MIRN ($15373), MIPN ($15695), OPN ($16986) and ORN ($17803).
Although not the predominant treatment approach for SRM over the study period, the use of NSS increased and was associated with improved survival, fewer complications and less renal insufficiency. Minimally-invasive approaches confer lower costs.
研究背景:回顾性数据表明,与根治性肾切除术相比,部分肾切除术可使患者的生存获益增加,这可能是因为避免了长期肾功能不全和随后的后遗症。然而,最近的一级证据对这一益处提出了质疑。回顾性研究和随机对照试验都有其局限性。关于部分肾切除术与根治性肾切除术的结果,几乎没有基于人群的数据。此外,还没有基于人群的研究分析手术方法(微创与开放)以及消融和监测等其他方法。最后,关于每种方法的潜在成本差异的信息非常有限。本研究是首次对 2005 年至 2007 年间 T1a 肾肿瘤的所有治疗方式的趋势、结果和成本进行的全面基于人群的分析。
目的:采用基于人群的方法对小肾肿瘤(SRM)的治疗结果和成本进行全面分析。部分肾切除术可能与生存改善相关,尽管一级证据对这种生存优势提出了质疑。
患者和方法:利用监测、流行病学和最终结果-医疗保险数据,我们从 2005 年至 2007 年确定了 1682 名被诊断为 SRM 的患者。治疗包括开放性根治性肾切除术(ORN;n = 404)、微创根治性肾切除术(MIRN;n = 535)、开放性部分肾切除术(OPN;n = 330)、微创部分肾切除术(MIPN;n = 160)、消融(n = 211)和监测(n = 42)。比较了术后并发症、肾功能不全诊断、总死亡率、癌症特异性死亡率和术后成本。在进行结果分析之前,使用倾向评分方法平衡了协变量。
结果:尽管在研究期间,保肾手术(NSS)的应用有所增加,但 2007 年根治性肾切除术仍是 SRM 的主要治疗方法。微创方法的住院时间更短(P < 0.001),而开放方法的总体并发症、呼吸并发症和重症监护病房入院率更高(均 P < 0.003)。MIRN 和 ORN 与围手术期更多的医疗并发症、急性肾衰竭、血液透析使用和长期慢性肾功能不全诊断相关(均 P < 0.001)。消融、MIRN 和 ORN 与总死亡率最高(P < 0.001)相关,而 MIRN 和 ORN 与癌症特异性死亡率最高(P < 0.001)相关。监测(2911 美元)、消融(10730 美元)、MIRN(15373 美元)、MIPN(15695 美元)、OPN(16986 美元)和 ORN(17803 美元)的治疗费用最低。
结论:尽管在研究期间,NSS 不是 SRM 的主要治疗方法,但它的应用有所增加,并与生存改善、并发症减少和肾功能不全减少相关。微创方法降低了成本。